Group items tagged

The UK Health Security Agency on Friday said it had designated a sub-lineage of the dominant and highly transmissible Omicron coronavirus variant as a variant under investigation. BA.2, which does not have the specific mutation seen with Omicron that can be used as a proxy to easily distinguish it from Delta, is being investigated but has not been designated a variant of concern. "It is the nature of viruses to evolve and mutate, so it's to be expected that we will continue to see new variants emerge," Dr Meera Chand, incident director at the UKHSA, said. "Our continued genomic surveillance allows us to detect them and assess whether they are significant." Britain had identified 53 sequences of the BA.2 sub-lineage as of January 10, with updated figures due to be published later on Friday.

New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence. UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases. "Those who have never received a measles vaccine (MMR) are at risk," said UKHSA. MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward. Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s ('Wakefield cohorts') and some may still not be fully vaccinated. As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.

A total of 7,599 whooping cough cases have been recorded in England from January to May 2024, according to new data released by the UK Health Security Agency (UKHSA). In January 2024, there were 555 cases, followed by 920 in February, 1,427 in March, 2,106 in April, and 2,591 in May. While the majority of cases (over 53 per cent) occurred in individuals aged 15 years or older, who typically experience milder symptoms, a significant number (262) were reported in babies under 3 months old, who are at the highest risk of severe complications and death from whooping cough. Since the outbreak began in November last year, there have been nine infant deaths (one in December 2023 and eight between January and May 2024). Whooping cough, or pertussis, is a bacterial infection affecting the lungs. This cyclical disease peaks every 3 to 5 years, with the last increase seen in 2016.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

Both head of customer operations Dan Britton and chief executive Michael Brodie at the NHS Business Services Authority (NHSBSA) have won the Inspiring Leaders Award, which recognises leaders for their humanity and courage. The coveted award, organised by Inspiring Workplaces, recognised their contribution during the pandemic. Under Brodie's leadership, who joined the organisation as chief executive in September 2019, NHSBSA started over 50 new services to support the wider NHS. He also led Public Health England (PHE) through its transition to the new UK Health Security Agency. Miranda Sykes, head of communications and marketing at NHSBSA said: "Michael is an inspirational leader for many reasons. He cares immensely and he's spent the pandemic thinking about others and using his influence to support the NHS over the last 18 months or so." His decision to take up an additional CEO role while transforming the PHE during the pandemic shows "Michael's style of leadership is authentic, inclusive and empathetic. He is passionate about the NHS and doing everything he can to support it."

A person in England has been diagnosed with a rare viral monkeypox infection thought to be linked to travel to West Africa, health authorities said at the weekend (May 7). The UK Health Security Agency (UKHSA) said in a statement the case, in a person who had recently traveled to Nigeria, was being treated at an expert respiratory infectious disease unit at Guy's and St Thomas' NHS Foundation Trust in London. "It is important to emphasise that monkeypox does not spread easily between people and the overall risk to the general public is very low," said Colin Brown, director of clinical and emerging infections at UKHSA.

There is no sign of a surge of the Omicron coronavirus variant in Britain so far, the chief of the UK Health Security Agency said on Tuesday, adding that there was no rise in the proportion of tests with a quirk that distinguishes it from Delta. Jenny Harries said there were five confirmed Omicron cases in England and 10 "highly likely" cases, but that was not a sign of an increase in "S-gene target failure" in PCR tests in Britain, which is a feature of Omicron. "Right across the country we watch for… S-gene target failure, which is a sort of proxy measure," Harries told BBC radio. Cases with S-gene target failure can then be prioritised for full genomic sequencing.

The UK Health Security Agency (UKHSA) has warned that there has been a continued increase in cases of whooping cough (pertussis) across England since the start of this year. According to new data published by the agency on Thursday (7 March), 553 new cases of whooping cough were confirmed in January alone, compared with 858 cases for the whole of last year (2023). The country is witnessing a surge in whooping cough cases after a prolonged period of low case numbers, attributed to restrictions and reduced social interaction during the COVID-19 pandemic. England recorded the highest number of whooping cough cases in 2016, recording 5,949 cases. As the ongoing rise coincides with a steady decline in the vaccination rates among pregnant women and children, UKHSA has strongly encouraged mums-to-be to get the maternal pertussis vaccine so that their young baby is protected against this serious disease.

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the Pharmacy First service, which was launched across England in January 2024. They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment. After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo, shingles, infected insect bites or uncomplicated urinary tract infections in women. The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and Nottingham on the project. Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's impact on GPs and the wider NHS, pharmacy services and patients."

Community pharmacy contractors can now submit their December 2021 claims for the Pharmacy Collect service by the end of January 2022. Considering high demand for Lateral Flow Device (LFD) test kits, the UK Health Security Agency, Department of Health and Social Care, and NHS England and NHS Improvement have agreed to extend the submission deadline "on an exceptional basis." For December 2021 claims, contractors must make submissions before 11.59pm on January 31, 2022, Pharmaceutical Services Negotiating Committee (PSNC) has informed.

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

The government will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an "urgent reversal" to a fall in uptake as the country faces a worsening measles outbreak. Routine childhood immunisations in Britain for diseases including measles, mumps and rubella, diphtheria and polio, have been falling gradually over the past decade, but dipped more sharply after the Covid-19 pandemic, mirroring a global decline. Last year UNICEF said people worldwide had lost confidence in the importance of routine childhood vaccines during the pandemic, with misinformation, dwindling trust in governments and political polarisation contributing to rising hesitancy. Britons will begin seeing adverts from next week across various media, including a television campaign featuring children reminding parents of the risk of missing out on vaccinations, the UK Health Security Agency (UKHSA) said. "We need an urgent reversal of the decline in the uptake of childhood vaccinations to protect our communities," UKHSA chief executive Jenny Harries said in a statement.

In a collaborative effort, the National Health Services England (NHSE) is set to deliver the RSV(respiratory syncytial virus) vaccination programme where pharmacists alongside other healthcare professionals will play a crucial role in administering the vaccine. The UK Health Security Agency has announced the launch of the new vaccination programme targeting the respiratory syncytial virus (RSV), set to begin on 1 September 2024. Along with GPs, NHS England (NHSE) will "commission a number of community pharmacies to deliver the programme", ensuring broad accessibility and coverage to protect two high-risk groups: older adults and pregnant women. RSV is an RNA virus related to mumps, measles, and human parainfluenza viruses. It commonly causes coughs and colds in winter, transmitted through droplets and secretions from close contact with infected individuals. While most RSV infections are mild, infants under six months and the elderly are particularly susceptible to severe diseases like bronchiolitis and pneumonia, which can lead to hospitalisation.

The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter. The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2). UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023. Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.

As an unprecedented demand for Lateral Flow Device (LFD) test kits continues through the Pharmacy Collect service, the UK Health Security Agency (UKHSA) is planning to distribute 10.5 million tests per week via Alliance Healthcare this month. By the end of this week (January 8), the UKHSA aims to distribute more than 8 million tests to Alliance Healthcare - sole distributor to pharmacies. The announcement comes after many in the pharmacy sector voiced concerns over shortage of test kits. Earlier this week, it emerged that Alliance Healthcare closed for four days shortly after receiving around 2.5 million tests on Christmas Eve. Meanwhile, the UKHSA indicated that Alliance Healthcare has been delivering 86 per cent of its orders within 24 hours of the pharmacy order, nearly half of that on the same day. Besides, a plan to switch on a Parcel Force delivery contingency is being finalised by UKHSA, which would enable supply of a further 3.5 million test kits.

A fourth dose of Covid-19 vaccine is not needed at present, as latest data shows first booster provides high levels of protection against Omicron variant among older adults, says the Joint Committee on Vaccination and Immunisation (JCVI). After analysing latest data from the UK Health Security Agency (UKHSA), JCVI said: "There is no immediate need to introduce a second booster dose, or fourth jab, to the most vulnerable". Data from UKSHA revealed that single booster dose provides around 90 per cent protection against hospitalisation to those aged 65 and over, even after three months of jab. However, protection against mild symptomatic infection is short-lived and drops to around 30 per cent by about three months. The study, which looked at booster doses in those aged over 65, showed that with two vaccine doses, protection against the infection drops to around 70 per cent after three months and to 50 per cent after six months.

The UK Health Security Agency (UKHSA) has advised self-isolation for people diagnosed with monkeypox to reduce the risk of spreading the infection. Household members are at the highest risk of becoming infected from a case within their house. The new guidance advises people with monkeypox infection to take steps to try and limit transmission within the household. "Monkeypox infection mainly spreads between people through direct, skin-to-skin contact, including sexual contact. Infection can also be spread via contaminated objects such as linen and soft furnishings," said UKHSA. The guidance advises that, where possible, cases are encouraged to sleep and eat in a separate room and use a separate bathroom to their household if possible. Good hygiene measures, to follow at all times, have also been set out. It suggests, "Where the use of a separate room isn't possible, cases should avoid physical contact and keep at least three steps (one metre) away from all household members. It is particularly important that they avoid close contact with young children, pregnant women and immunosuppressed people as they may be at higher risk of serious illness."

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Additionally, children living with someone immunosuppressed will be eligible to get the first dose of the Covid-19 vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS, there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

A smattering of monkeypox cases in Britain has prompted authorities to offer a smallpox vaccine to some healthcare workers and others who may have been exposed, as a handful more cases were confirmed in parts of Europe. Monkeypox is a usually mild viral illness, characterised by symptoms of fever as well as a distinctive bumpy rash. There are two main strains: the Congo strain, which is more severe - with up to 10 per cent mortality - and the West African strain, which has a fatality rate of about one per cent First identified in monkeys, the viral disease typically spreads through close contact and largely occurs in west and central Africa. It has rarely spread elsewhere, so this fresh spate of cases outside the continent has triggered concern. In the United Kingdom, nine cases of the West African strain have been reported so far. There isn't a specific vaccine for monkeypox, but a smallpox vaccine does offer some protection, a UK Health Security Agency (UKHSA) spokesperson said. Data shows that vaccines that were used to eradicate smallpox are up to 85 per cent effective against monkeypox, according to the World Health Organisation.